The start of licensing procedures for the German "Corona" vaccine

The German pharmaceutical company, "Biontech", began procedures for obtaining a license for its emerging coronavirus vaccine.

And participate "Pfizer" American in developing this vaccine.

The procedure includes presenting data obtained from clinical trials.

The European Medicines Agency (EMA) will examine the active ingredient of the BNT162B2 vaccine as part of what is called the current review procedures, according to this procedure, according to Biontech and the American company, Pfizer, which is involved in developing this vaccine, in this procedure. Data obtained from clinical trials are presented and evaluated on an ongoing basis.

The European Medicines Agency's decision to initiate this procedure is based on what it obtained from encouraging preliminary data from clinical, preclinical and early trials in adults.

It is entirely possible that the interim evaluation will provide good data on the effectiveness of the vaccine and how safe it is to use it, said Klaus Sischottik, president of the Paul Ehrlich Institute (PEI) in charge of vaccines and biomedicine, and accordingly, a so-called "conditional marketing license" could be granted before the start of the third phase. Clinical trials, which take between one to two years.

Follow our latest local and sports news, and the latest political and economic developments via Google news